Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Egg Consumption and Mortality Due to Cardiovascular Events

According to this study recently published in prestigious journal JAMA, eating too much cholesterol or eggs (which have a high concentration of it in the yolk) is significantly associated with a higher risk of cardiovascular events and all-cause mortality, with a typical dose/effect curve. According to the authors, this information should be considered for an update of current dietary guidelines.

colesterol ldl placas coronarias

Cholesterol is a common nutrient in any non-vegan diet and eggs are its main source. Recommendations on egg consumption have seen many different stages: from regarding it as “public enemy #1” to encouraging its consumption. This work seeks to put an end to controversy and deliver definitive information.

This analysis included 29,615 participants with a mean age of about 50 years old and a mean follow-up of 17.5 years.

For each additional 300 mg of dietary cholesterol consumed per day (very hard to measure in daily practice) or each additional half an egg per day (much easier to measure), there was a significant increase in cardiovascular events (adjusted hazard ratio [HR]: 1.17; 95% confidence interval [CI]: 1.09 to 1.26) and all-cause mortality (adjusted HR: 1.18; 95% CI: 1.10 to 1.26).


Read also: Strict LDL Monitoring Helps Reduce Plaque Volume.


The association between egg consumption and cardiovascular events or all-cause death was no longer significant after adjusting for dietary cholesterol consumption. This might mean that the problem lies in cholesterol itself, and that eggs are simply an easy way to measure it. There might not be any additional deleterious component (other than cholesterol) in eggs. Reducing egg consumption ultimately reduces cholesterol consumption.

Original Title: Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality.

Reference: Victor W. Zhong et al. JAMA. 2019;321(11):1081-1095.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...